1. Home
  2. BOLD vs RDI Comparison

BOLD vs RDI Comparison

Compare BOLD & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • RDI
  • Stock Information
  • Founded
  • BOLD 2018
  • RDI 1937
  • Country
  • BOLD United States
  • RDI United States
  • Employees
  • BOLD N/A
  • RDI N/A
  • Industry
  • BOLD
  • RDI Movies/Entertainment
  • Sector
  • BOLD
  • RDI Consumer Discretionary
  • Exchange
  • BOLD Nasdaq
  • RDI Nasdaq
  • Market Cap
  • BOLD 24.4M
  • RDI 27.9M
  • IPO Year
  • BOLD 2024
  • RDI N/A
  • Fundamental
  • Price
  • BOLD $1.19
  • RDI $1.30
  • Analyst Decision
  • BOLD Buy
  • RDI
  • Analyst Count
  • BOLD 3
  • RDI 0
  • Target Price
  • BOLD $4.00
  • RDI N/A
  • AVG Volume (30 Days)
  • BOLD 105.1K
  • RDI 26.9K
  • Earning Date
  • BOLD 08-11-2025
  • RDI 08-13-2025
  • Dividend Yield
  • BOLD N/A
  • RDI N/A
  • EPS Growth
  • BOLD N/A
  • RDI N/A
  • EPS
  • BOLD N/A
  • RDI N/A
  • Revenue
  • BOLD N/A
  • RDI $205,644,000.00
  • Revenue This Year
  • BOLD N/A
  • RDI $7.47
  • Revenue Next Year
  • BOLD N/A
  • RDI $13.22
  • P/E Ratio
  • BOLD N/A
  • RDI N/A
  • Revenue Growth
  • BOLD N/A
  • RDI N/A
  • 52 Week Low
  • BOLD $1.00
  • RDI $1.17
  • 52 Week High
  • BOLD $4.72
  • RDI $1.89
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • RDI 46.02
  • Support Level
  • BOLD N/A
  • RDI $1.27
  • Resistance Level
  • BOLD N/A
  • RDI $1.45
  • Average True Range (ATR)
  • BOLD 0.00
  • RDI 0.06
  • MACD
  • BOLD 0.00
  • RDI 0.00
  • Stochastic Oscillator
  • BOLD 0.00
  • RDI 16.67

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: